Moleculin Biotech
MBRX
24 hedge funds and large institutions have $3.71M invested in Moleculin Biotech in 2020 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 6 closing their positions.
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
41% more funds holding
Funds holding: 17 → 24 (+7)
28% more capital invested
Capital invested by funds: $2.91M → $3.71M (+$809K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$109K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$107K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$83K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$68.8K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$42.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.16M |
| 2 |
BlackRock
New York
|
-$102K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$55K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$44K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$22K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PFO
26
Pathstone Family Office
Englewood,
New Jersey
| $1K | – | – | – |
|
|
PWMG
27
Prestige Wealth Management Group
Flemington,
New Jersey
| $1K | – | – | – |
|
28
Barclays
London,
United Kingdom
| $1K | +$2.37K | +1 | New |
|
|
TSS
29
Two Sigma Securities
New York
| – | -$55K | -40 | Closed |
|
|
RJFSA
30
Raymond James Financial Services Advisors
St. Petersburg,
Florida
| – | -$44K | -32 | Closed |
|
|
31
Citadel Advisors
Miami,
Florida
| – | -$22K | -16 | Closed |
|
32
Victory Capital Management
San Antonio,
Texas
| – | -$10K | -7 | Closed |
|
|
PFGIA
33
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| – | -$2K | -1 | Closed |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$2.37K | -1 | Closed |
|
MBRX Hedge Fund Activity: Q2 2020 in Review
24 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q2 2020, worth a combined $3.71M — up 28% from $2.91M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MBRX positions and 6 closed out — a net gain of 7 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $109K. The largest seller was Vanguard Group, cutting an estimated $1.16M.
- 24 institutional investors held Moleculin Biotech (MBRX) as of Q2 2020, up from 17 in Q1 2020.
- Funds reported $3.71M of Moleculin Biotech stock for Q2 2020, up 28% quarter-over-quarter.
- 13 funds opened new Moleculin Biotech positions in Q2 2020 and 6 closed out, a net change of +7 holders.
- The largest Moleculin Biotech buyer in Q2 2020 was Renaissance Technologies, an estimated $109K added.
- The largest Moleculin Biotech seller in Q2 2020 was Vanguard Group, an estimated $1.16M sold.
Based on aggregated 13F filings for Q2 2020.